The granted claims of the patent include the class of selective serotonin receptor affinity compounds discovered by Suven and are being developed as therapeutic agents.
Venkat Jasti, CEO of Suven, said: “We are very pleased by the issuance of this patent to Suven by US Patent office for our drug candidates that are being developed for CNS disorders which targets a $18 billion potential market opportunity.”